Australia's most trusted
source of pharma news
Posted 14 October 2021 AM
MSD's blockbuster Keytruda has had another huge run with the TGA revealing it approved three new indications for the drug last month.
Two of the three new indications were registered via the provisional approval pathway, enabling earlier access to the checkpoint inhibitor for patients with Tumour Mutational Burden-High (TMB-H) cancer and the second most common form of skin cancer.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.